APEN News and Press, Apollo Endosurgery Inc. From 03/01/21

Apollo Endosurgery (APEN) rallies 35% premarket after receiving FDA Breakthrough Device Designation for the Orbera Intragastric Balloon, for use in treating patients with BMI between 30-40 kg/m2 with noncirrhotic nonalcoholic steatohepatitis ((NASH)) with liver fibrosis.he desi...

ASLAN Pharmaceuticals Limited (ASLN) +71% as ASLAN004 shows positive effect in atopic dermatitis.Apollo Endosurgery (APEN) +47% after receiving a Breakthrough Device Designation from the USFDA for the Orbera® Intragastric Balloon.electroCore (ECOR) +39% on exclusive distri...

AUSTIN, TX / ACCESSWIRE / March 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that it has received a Breakthrough Device Designation from the U.S. Food and Drug...

Apollo Endosurgery, Inc. (APEN) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Matt Kreps - IR Todd Newton - CEO Stefanie Cavanaugh - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Presentation Operator Good afternoon, ladies and ...

Apollo Endosurgery (APEN): Q4 GAAP EPS of -$0.14 beats by $0.12.Revenue of $12.86M (+7.3% Y/Y) beats by $1.85M.Press Release For further details see: Apollo Endosurgery EPS beats by $0.12, beats on revenue

Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / February 25, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financ...

AUSTIN, TX / ACCESSWIRE / February 22, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial resul...

Apollo Endosurgery ([[APEN]] +12.3%) announced a planned CEO change; effective Mar.1, Charles (Chas) McKhann will become CEO and a board member.Current CEO Todd Newton will assist in an effective transition to Mr. McKhann and has agreed to serve as a consultant t...

Will Transition to Accomplished Commercial and Operational Medtech Veteran Charles Mckhann AUSTIN, TX / ACCESSWIRE / February 8 , 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and b...

AUSTIN, TX / ACCESSWIRE / January 5, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the H.C. Wainwright Bioconnect 2021 Conference taking pl...